This is what analysts have to say about Regulus Therapeutics Inc. (NASDAQ:RGLS) after last week.

April 21, 2018 - By Marguerite Chambers

Regulus Therapeutics Inc. (NASDAQ:RGLS) LogoInvestors sentiment decreased to 1.16 in 2017 Q4. Its down 0.19, from 1.35 in 2017Q3. It dropped, as 7 investors sold Regulus Therapeutics Inc. shares while 12 reduced holdings. 10 funds opened positions while 12 raised stakes. 53.17 million shares or 9.64% less from 58.85 million shares in 2017Q3 were reported.
Moreover, Laurion Mgmt L P has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 392,310 shares. 137,589 are held by Renaissance Technology Ltd Liability Company. D E Shaw & accumulated 0% or 27,319 shares. Manufacturers Life Insur The accumulated 6,057 shares. Geode Mngmt Ltd Co has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). 98 are owned by Deutsche Natl Bank Ag. 492,878 are owned by Rhenman And Prtnrs Asset Management Ab. Moreover, Susquehanna Intll Gp Ltd Liability Partnership has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 32,631 shares. Quantitative Inv Limited Liability Company accumulated 0% or 45,800 shares. Washington Comml Bank holds 0% or 155 shares. California Pub Employees Retirement Systems holds 177,600 shares. Northern Trust Corporation holds 187,492 shares. Brookstone Cap Management stated it has 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Blackrock reported 0% stake. Nea Ltd Liability invested in 0.47% or 10.99M shares.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Regulus Therapeutics had 9 analyst reports since November 8, 2017 according to SRatingsIntel. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Buy” rating by Wedbush on Monday, March 12. Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Monday, December 11. Wedbush has “Buy” rating and $4.0 target. FBR Capital initiated Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Tuesday, March 27. FBR Capital has “Hold” rating and $100 target. The rating was maintained by BMO Capital Markets on Thursday, March 8 with “Market Perform”. The rating was maintained by Wedbush on Thursday, February 8 with “Buy”. On Wednesday, November 8 the stock rating was maintained by BMO Capital Markets with “Market Perform”. Wedbush maintained the stock with “Buy” rating in Wednesday, December 20 report. Below is a list of Regulus Therapeutics Inc. (NASDAQ:RGLS) latest ratings and price target changes.

28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On
20/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
11/12/2017 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
08/11/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $1.15 New Target: $1 Maintain

The stock decreased 0.94% or $0.0062 during the last trading session, reaching $0.6534. About 198,222 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 52.76% since April 21, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $67.93 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.